Laronde eRNA Therapeutics

Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering  and is pathfinding a platform that offers a completely novel way of modulating human biology.  Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse therapeutic proteins inside the body.  It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.

Avak Kahvejian, Ph.D., Co-Founder and Board Member of Laronde, and General Partner, Flagship Pioneering, recently commented that “Over the past few years, we have seen how programmable platforms like translatable mRNA can rapidly bring forward new medicines.  eRNA solves many of the limitations of other drug modalities and unlocks new opportunities for creating first- and best-in-class therapeutics.”

Laronde continues to advance the exciting new science of eRNA and has already been able to demonstrate controlled expression of secreted peptides, proteins, antibodies, and vaccine constructs in vivo through a number of delivery mechanisms.  The eRNA platform’s programmability and unique pharmacology promises accelerated development and a increased program success versus more traditional biotech programs.

In August 2021, the JIMCO Life Sciences Fund participated in Laronde’s Series B funding round to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.